NCT05111561 - Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

March 14, 2027

Study Completion Date

March 14, 2027

Conditions

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmTriple-Negative Breast CarcinomaUnresectable Malignant Solid Neoplasm

Interventions

DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

DRUG

Binimetinib

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (4)

77030

RECRUITING

M D Anderson Cancer Center, Houston

02118

SUSPENDED

Boston Medical Center, Boston

02215

SUSPENDED

Dana-Farber Cancer Institute, Boston

77555-0565

RECRUITING

University of Texas Medical Branch, Galveston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH